Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06616844 · ClinicalTrials.gov registry record · NA

IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers

A NA study of Wound Heal and Ulcer, sponsored by ConvaTec.

Recruiting
Registry status
NA
Development phase
194
Enrollment target
9
Study locations

NCT06616844: Recruiting NA study of Wound Heal and Ulcer, sponsored by ConvaTec.

NCT06616844 is a NA study of Wound Heal and Ulcer that is actively recruiting participants, run by ConvaTec. The registered enrollment target is 194 participants, above the 111-participant average among 23 other Wound Heal trials with a reported enrollment target (75% higher). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06616844, a NA study of Wound Heal and Ulcer, is actively recruiting participants, sponsored by ConvaTec.

RECRUITING
Registry status
NA
Development phase
194 participants
Enrollment target
9
Study locations

Study Summary

A multi-center, prospective, observer-blinded, randomized controlled clinical trial to evaluate the efficacy of PPECM augmented standard of care versus standard of care alone in the management of hard-to-heal diabetic foot ulcers.

Primary Outcome

Measure the incidence of complete wound closure, defined as 100% reepithelialization of the wound without drainage, confirmed at a second clinical visit occurring at least 2-weeks after the visit where wound closure was initially observed

Conditions Studied

Interventions

  • DEVICE InnovaMatrix® AC

Study Locations (9)

California

  • Angel City Research - Los Angeles
  • Center for Clinical Research - San Francisco
  • ILD Research Center - Vista

Florida

  • Dinamo Research and Diagnostic Center - Hialeah

Indiana

  • Indiana Foot & Ankle - Jasper

Maryland

  • US-FAS - Hagerstown

Massachusetts

  • Boston Medical Center - Boston

New York

  • Northwell Health Comprehensive Wound Healing Center - New Hyde Park

North Carolina

  • US-FAS - Raleigh

Trial Details

FieldValue
Enrollment Target 194 participants
Start Date 2025-02-12
Est. Completion 2026-07
Phase NA
ConvaTec

17 total trials

What NCT06616844 shows while recruiting

NCT06616844 is an interventional study that assigns participants to a tested intervention. The registered 194 participants enrollment target is mid-sized for trials with a published cap, above the 111-participant average among 23 other Wound Heal trials with a reported enrollment target (75% higher).

The record links to 2 conditions, with Wound Heal appearing as the primary indexed condition, and to 1 intervention - of which InnovaMatrix® AC is the first listed.

NCT06616844 lists 9 locations in 7 states (California, Florida, Indiana).

Frequently Asked Questions

What is clinical trial NCT06616844 about?

NCT06616844 is a clinical study titled "IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers". A multi-center, prospective, observer-blinded, randomized controlled clinical trial to evaluate the efficacy of PPECM augmented standard of care versus standard of care alone in the management of hard-to-heal diabetic foot ulcers.

What is the current status of trial NCT06616844?

This trial is currently recruiting. It is a NA study. The enrollment target is 194 participants. The study started on 2025-02-12. Estimated completion is 2026-07.

What conditions does trial NCT06616844 study?

This clinical trial studies the following conditions: Wound Heal, Ulcer.

What interventions are being tested in trial NCT06616844?

The interventions under investigation include: InnovaMatrix® AC (DEVICE).

Who is sponsoring clinical trial NCT06616844?

This trial is sponsored by ConvaTec, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06616844 being conducted?

This trial has 9 study locations across California, Florida, Indiana, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Wound Heal

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06616844's enrollment target sits among peer trials

194 6th of 23 higher than 18 of 23 other Wound Heal trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Wound Heal trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03593759 · 194 participants · Phase 3

    Cardiac Sarcoidosis Randomized Trial

  • NCT05053152 · 194 participants · Phase 2

    Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

  • NCT05156112 · 194 participants · NA

    OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit

  • NCT05351424 · 194 participants · NA

    AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06616844, the US trial registry maintained by the National Library of Medicine. NCT06616844 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.